Risk factors and surgical outcomes in periocular basal cell carcinoma treated with Mohs micrographic surgery
Glaysson Tassara Tavares, Alberto Julius Alves Wainstein, João Renato Vianna Gontijo, Ana Paula Drumond Lage

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsNonmelanoma Skin Cancer Studies · Reconstructive Facial Surgery Techniques · Corneal Surgery and Treatments
Dear Editor,
Periocular basal cell carcinoma (BCC) represents a therapeutic challenge due to its invasive behavior and proximity to critical anatomical structures. Few studies have evaluated its predictors of aggressiveness and recurrence treated with Mohs micrographic surgery (MMS).
A retrospective cohort study was conducted at a Brazilian multidisciplinary center by a single surgeon (maintaining the same surgical technique standard). Patients with periocular BCC treated with MMS between 2008 and 2018 were included.
Data were collected on sex, age, tumor location, aggressive histological subtype (micronodular, sclerosing, infiltrative, and metatypical/basosquamous) or non-aggressive (superficial, nodular), tumor diameter (> 10 mm or ≤ 10 mm), prior Mohs surgery recurrence (PMSR), MMS stages, type of reconstruction, follow-up, and postoperative recurrence. Cases with perineural invasion (two) and prior radiotherapy (none) were excluded because they are already established high-risk factors, for homogenization of the statistical sample, and because there were few cases. In cases with mixed subtypes, the most aggressive was considered. Reconstructions were classified based on non-standardized criteria as minor (primary closure, small flaps, canthotomy-cantholysis), moderate (Tenzel flap), and significant (Hughes or Mustardé flaps), according to the size of the defect and structures involved (up to 25%–30%, 30% to 60%, and above 60% of the eyelid margin, respectively). For cases without involvement of the eyelid margin, those requiring the Mustardé flap were considered significant, while the others were considered minor.
The statistical analysis included descriptive statistics, the Shapiro-Wilk test, the Wilcoxon test, Fisher's exact test, and the Kruskal-Wallis test (p < 0.05). Logistic regression models were used, with variable selection based on the calculation of Akaike's information criterion.
One hundred and eight patients were included, 57.1% female, mean age 66.3 years (±15.1; 27–91 years). The lower eyelid was the most affected site (55.5%) and medial canthus (29.7%), consistent with other literature studies on MMS in this location (51%).1 Aggressive subtypes were present in 66.1%. Tumors with a diameter > 10 mm were observed in 49.1%, and 8% presented with PMSR. Recurrence after MMS occurred in 3.8% (n = 4), with a follow-up of 64.8 months (±31.6), similar to previous studies with recurrence of 3%–3.3% in similar cohorts.2, 3 The mean tumor area was 96 mm^2^ and the mean final area was 398 mm^2^. Reconstructions were minor (62%), moderate (13%), and significant (25%).
More stages of MMS were associated with PMSR (2.9 ± 1.5) vs. primary BCC (2.0 ± 1.1; p = 0.002), diameter > 10 mm (2.6 ± 1.4) vs. < 10 mm (1.9 ± 1.1; p = 0.007), and aggressive histology (2.4 ± 1.1) vs. non-aggressive (2.0 ± 1.5; p = 0.005).
Table 1, through univariate logistic regression, exemplifies that tumors > 10 mm were strongly associated with aggressive histology (OR = 7.33; p < 0.001) and larger defect area (OR = 1.008; p < 0.001). Tumors with PMSR showed a greater number of stages (OR = 1.72; p = 0.002), a larger defect area (OR = 1.008; p = 0.001), and more significant reconstructions (OR = 2.73; p = 0.039). Tumors with aggressive histology exhibited a greater chance of complex reconstructions (OR = 4.53; p = 0.006).Table 1. Univariate logistic regression model of variables associated with the main surgical outcomes in periocular basal cell carcinoma. Pre-operative Mohs surgical recurrence (PMSR), Odds ratio (OR).Table 1. OutcomeVariablep-valueOdds ratio (OR)Confidence IntervalDiameter > 10 mmPMSR<0.0015.8752.413-15.635Stages0.0081.5751.142-2.256Defect area<0.0011.0081.005-1.012Aggressive histology<0.0017.3333.093-18.848Moderate reconstruction0.8290.8760.246-2.832Significant reconstruction<0.0016.9382.494-22.807PMSRDiameter >10 mm<0.0015.8752.413-15.635Stages0.0021.7211.236-2.485Defect area0.0011.0081.005-1.012Aggressive histology0.1581.8730.8-4.623Moderate reconstruction0.1542.3910.697-7.945Significant reconstruction0.0392.7321.05-7.169Aggressive histologyDiameter > 10 mm<0.0017.3333.093-18.848Stages0.0721.3640.988-1.954Defect area0.0661.0011-1.002PMSR0.1581.8730.8-4.623Moderate reconstruction0.0563.7781.067-17.817Significant reconstruction0.064.5331.636-14.815
Table 2 using the multivariate model indicated that PMSR was associated with a larger defect area (OR = 1.002; p = 0.001) and significant reconstruction (OR = 3.77; p = 0.0177), as well as previous studies that demonstrated that lesions previously inadequately treated by conventional surgery tend to exhibit increased/more aggressive subclinical growth and behavior when recurring locally.4, 5 Tumors > 10 mm were associated with PMSR (OR = 8.02; p = 0.0148), aggressive subtype (OR = 8.41; p = 0.0021) and larger defect area (OR = 1.006; p = 0.0017). Aggressive histology was associated with a diameter > 10 mm (OR = 6.92; p < 0.001).Table 2. Multivariate logistic regression for outcomes of diameter > 10 mm, prior Mohs micrographic surgery recurrence (PMSR), and aggressive histological subtype. Odds ratio (OR).Table 2. OutcomeVariableOdds Ratio (OR)Confidence Intervalp-valueDiameter > 10 mmDefect area1.0061.003–1.0100.0017PMSR8.0231.688–52.4220.0148Aggressive histology8.4122.316–36.8260.0021PMSRDefect area1.0021.001–1.0040.0007Significant reconstruction3.7651.256–11.5100.0177Aggressive histologyDiameter > 10 mm6.9222.724–19.070<0.001Moderate reconstruction4.9441.271–24.9440.0305
The anatomical distribution and cure rate (3.8%) after MMS are aligned with the literature, as in Shi et al. 4.2% (n = 167), with the lower eyelid and medial canthus being the most frequent sites.1, 2, 3, 6, 7, 8 The initial descriptive analysis revealed associations between a higher number of MMS stages and tumors with aggressive histology, diameter > 10 mm, and PMSR, as described in previous studies.4, 9
The univariate analysis reinforced that larger tumors, aggressive histology, or those with PMSR exhibit a greater chance of subclinical growth and complex reconstructions.
The multivariate analysis confirmed these findings; however, it showed that tumors with PMSR and tumors > 10 mm were almost seven times more likely to have aggressive histology. Although modest, the differences in the area of the final defect were statistically significant, highlighting the impact of these tumor characteristics on surgical extent. The findings suggest that larger tumors with aggressive histology require wider excisions.
Significant reconstructions were associated with PMSR (OR = 3.76), suggesting that recurrent tumors require more complex approaches. However, reconstructive complexity may reflect tumor biology/behavior (size, histological subtype), without being an independent predictor. As shown above, BCCs with PMSR tend to be aggressive subtypes and have a diameter > 10 mm.
The association between size, PMSR, and tumor aggressiveness reaffirms MMS as the preferred technique in these cases, given the higher chance of subclinical growth.4, 5, 9 Margin control is crucial, especially where conventional surgery is still common and access to MMS is limited, reducing the risks of invasive tumors.2, 3
The study limitations include its retrospective and single-center design, which may limit its findings. Larger studies may validate these associations and support individualized surgical planning.
ORCID ID
Alberto Julius Alves Wainstein: 0000-0002-8227-7972
Ana Paula Drumond Lage: 0000-0002-0389-2433
Joao Renato Vianna Gontijo: 0000-0001-5544-7107
Glaysson Tassara Tavares; 0000-0002-1688-2955
Financial support
None declared.
Authors' contributions
Glaysson Tassara Tavares: Drafting and editing of the manuscript; critical review of important intellectual content and approval of the final version of the manuscript.
Alberto Julius Alves Wainstein: Drafting and editing of the manuscript; critical review of important intellectual content and approval of the final version of the manuscript.
João Renato Vianna Gontijo: Drafting and editing of the manuscript; critical review of important intellectual content and approval of the final version of the manuscript.
Ana Paula Drumond Lage: Drafting and editing of the manuscript; critical review of important intellectual content and approval of the final version of the manuscript.
Research data availability
The entire dataset supporting the results of this study was published in this article.
Conflicts of interest
None declared.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Shi K.Wang L.Srivastava D.Nijhawan R.I.Mohs micrographic surgery for periocular skin cancer: a single-institution experience Arch Dermatol Res.3152023118111863646475710.1007/s 00403-022-02481-6 · doi ↗ · pubmed ↗
- 2Weesie F.Naus N.C.Vasilic D.Hollestein L.M.van den Bos R.R.Wakkee M.Recurrence of periocular basal cell carcinoma and squamous cell carcinoma after mohs micrographic surgery: a retrospective cohort study Br J Dermatol.1802019117611823053665610.1111/bjd.17516 PMC 6849866 · doi ↗ · pubmed ↗
- 3O’Halloran L.Smith H.Vinciullo C.Periocular mohs micrographic surgery in western Australia 2009–2012: a single centre retrospective review and proposal for practice benchmarks Australas J Dermatol.5820171061102676793110.1111/ajd.12432 · doi ↗ · pubmed ↗
- 4Fatigato G.Capitani S.Milani D.Grassilli S.Alameen A.A.M.Candiani M.Risk factors associated with relapse of eyelid basal cell carcinoma: results from a retrospective study of 142 patients Eur J Dermatol.2720173633682852405510.1684/ejd.2017.3026 · doi ↗ · pubmed ↗
- 5Moul D.K.Chern P.L.Shumaker P.R.Zelac D.E.Greenway H.T.Mohs micrographic surgery for eyelid and periorbital skin cancer Int Ophthalmol Clin.49200911112710.1097/IIO.0b 013e 3181 b 8048220348861 · doi ↗ · pubmed ↗
- 6Sines D.T.Polomsky M.Dutton J.J.Predicting the surgical margin of resection in periocular cutaneous neoplasms and the significance of reconstruction following mohs micrographic surgery Ophthalmic Plast Reconstr Surg.3220162842912623752910.1097/IOP.0000000000000505 · doi ↗ · pubmed ↗
- 7Sin C.W.Barua A.Cook A.Recurrence rates of periocular basal cell carcinoma following Mohs micrographic surgery: a retrospective study Int J Dermatol.552016104410472715274710.1111/ijd.13326 · doi ↗ · pubmed ↗
- 8Peirano D.Vargas S.Hidalgo L.Donoso F.Abusleme E.Sanhueza F.Management of periocular keratinocyte carcinomas with mohs micrographic surgery and predictors of complex reconstruction: a retrospective study An Bras Dermatol.9920242022093798968810.1016/j.abd.2023.05.004PMC 10943309 · doi ↗ · pubmed ↗
